d3-pcbanner-33.jpg d3-phbanner.jpg
Clinical Trials
A Randomized, Single blind, Placebo Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD4059 in Healthy Subjects

“A Randomized, Single-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects”, this study is ongoing in Australia. the study is currently in the single-dose incremental enrolment phase.

RBD4059 is a GalNAc-siRNA drug that inhibits FXI activity and prolongs APTT to achieve anticoagulant effects. As demonstrated in preclinical data, RBD4059 has a long-lasting and potent antithrombotic effect combined with a favorable safety profile. RBD4059 is the first FXI targeting siRNA drug that that has entered the clinical stage.

联系

如果您想了解更多关于本研究或研究药物的信息,欢迎联系项目负责人,她(他)将更为详细的为您介绍本项目,并安排您进行相应的检查。

石莹
ying.shi@smo-clinplus.com
冒建培
ianpei.mao@smo-clinplus.com
胡金慧
jinhui.hu@smo-clinplus.com